Vulvovaginal candidiasis
Conditions
Interventions
Placebo group:Clinical standard therapy was started on day T0, and after receiving antibiotics for 7 days, placebo was taken for 10 days from day T10.
Probiotic group:Clinical standard treatment was started on day T0, and after receiving antibiotics for 7 days, probiotic was taken continuously for 10 days from day T10, 1 pack/day.
Sponsors
Jiangsu Province Hospital of Integrated Chinese and Western Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: (1) 60 subjects with vulvovaginal candidiasis (18-50 years old), who received antibiotic treatment for 7 days, were randomly assigned to the experimental group and the control group. (2) Age 18-50 years old, previous regular menstrual cycle; (3) no hormones or other drugs affecting systemic immune function have been used within 3 months before the test; (4) no other endocrine, autoimmune, allergic diseases and reproductive system diseases; (5) Informed and consenting.
Exclusion criteria
Exclusion criteria: (1) Combined with endometriosis, uterine adenomyosis, uterine fibroids and other gynecological diseases; (2) Patients with serious diseases such as cardiovascular and cerebrovascular, liver, kidney, respiratory system and blood system; (3) Patients with acute and chronic infections, malignant tumors and other diseases; (4) Combined with endocrine system, autoimmune system diseases and infectious diseases; (5) Those who have fertility requirements within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginal itching, pain, edema, erosion degree;Vaginal flora sequencing; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fecal flora sequencing; | — |
Countries
China
Contacts
Public ContactJianhong Wang
Jiangsu Province Hospital of Integrated Chinese and Western Medicine
Outcome results
None listed